IRVINE, Calif., March 25 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, today announced an agreement with Switzerland-based Schiller, a leading European manufacturer and supplier of electrocardiographs, spirometers, patient monitors and external defibrillators, to integrate the Masimo Rainbow SET technology platform as the foundational technology of choice for all their patient monitoring solutions worldwide.
Masimo Rainbow SET, an upgradeable noninvasive technology platform featuring the accuracy and reliability of Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry, is revolutionizing patient monitoring by significantly expanding pulse oximetry's ability to capture, track and monitor blood constituents that previously required invasive procedures. The first and only technology platform capable of continuously and noninvasively measuring total hemoglobin (SpHb(TM)) and oxygen content (SpOC(TM)) (both pending FDA clearance), in addition to carboxyhemoglobin (SpCO(TM)), methemoglobin (SpMet(TM)), pleth variability index (PVI(TM)), oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate-Masimo Rainbow SET is helping to advance patient safety and improve care worldwide.
"Our leading position in the world market is based on a history of implementing new technologies and innovative first-class solutions that create long-term value for our customers and their patients," said Schiller AG CEO, Alfred Schiller. "Masimo understands the importance of cutting-edge technologies in our market and has combined the most advanced noninvasive technology and capabilities with the best user benefits available into a technology platform that maximizes long-term value."
The ability to quickly and continuously measure SpHb, SpOC, SpMet,
SpCO, PVI, SpO2, PR, and PI noninvasively may help clinicians to save lives
by more rapidly diagnosing potentially
Copyright©2008 PR Newswire.
All rights reserved